Search reports.
Skeletal Dysplasia Market Size, Share & Growth Report | 2030
Get free sample report Request for Customiztion Buy Now

Skeletal Dysplasia Market Size, Share & Growth Report | 2030

Segments - Global Skeletal Dysplasia Market by Types (X-linked Hypophosphatemia, Hypophosphatasia, Achondroplasia, Fibrodysplasia Ossificans Progressive, Multiple Osteochondromas, and Others), Treatments (Medications, Surgery, and Others), End-users (Hospitals, Ambulatory Surgical Centers, and Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecast, 2021-2028

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-952 | 4.8 Rating | 63 Reviews | 134 Pages | Format : PDF Excel PPT

Report Description


The global skeletal dysplasia market is anticipated to expand at a moderate CAGR during forecast period, between 2021 and 2028. The growth of the market is attributed to rising prevalence of skeletal dysplasia across the globe.

Skeletal dysplasia is a rare disease that is caused by a defect in a particular gene, known as a genetic mutation. Skeletal dysplasia is a group of diseases that constitute over 450 conditions in the skeleton. This disease affects the development and growth of the bone and cartilage. Skeletal dysplasia may lead to abnormalities related to bone size, density, shape, and short stature.

Symptoms of skeletal dysplasia include missing limbs, stubby fingers, missing ribs, fractured bones, joint pain, scoliosis, club feet, developmental delays, cognitive impairments, and duplication of fingers or toes. The common types of skeletal dysplasia include thanatophoric dysplasia, hypochondroplasia, campomelic dysplasia, osteogenesis imperfect, and achondrogenesis. The treatment of skeletal dysplasia mainly includes prescription of the growth hormones and surgical procedures.

Global Skeletal Dysplasia Market Summary

Market Trends, Drivers, Restraints, and Opportunities:

  • Factors such as commercialization of drugs and high number of drugs in pipeline for the treatment of skeletal dysplasia is anticipated to propel the market growth.
  • Poor diagnosis and less awareness related to the treatment of skeletal dysplasia are expected to hamper the market growth to a certain extent.
  • The emergence of drug therapies for the treatment of skeletal dysplasia is expected to provide an opportunity for the market growth in the coming years.

Scope of the report:

The report on skeletal dysplasia market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes

Details

Base Year

2020

Historic Data

2018 & 2019

Forecast Period

2021–2028

Regional Scope

Asia Pacific, North America, Europe, Latin America, and Middle East & Africa

Report Coverage

Market Scope, Analysis, Share, Competitive Analysis, Growth Facts, Restraints, Opportunities and Revenue Forecast

 

Skeletal Dysplasia Market Segment Insights:

Strong presence of pipeline products drives segment growth
On the basis of types, the global skeletal dysplasia market can be categorized as x-linked hypophosphatemia, hypophosphatasia, achondroplasia, fibrodysplasia ossificans progressive, multiple osteochondromas, and others. The fibrodysplasia ossificans progressive segment held a substantial market share and is expected to register significant CAGR during the forecast period. The segmental growth is attributed to the rising awareness of the disease and high number of pipeline products for the treatment of fibrodysplasia ossificans progressive disorder.

Global Skeletal Dysplasia Market By Type

Several benefits of surgery over other treatments is fueling the segmental growth
By treatments, the market can be segregated into medications, surgery, and others. The surgery segment is anticipated to expand at a considerable CAGR owing to the benefits such as faster outcomes and effectiveness of surgery over other treatments. Most of the patients prefer surgery, especially for achondroplasia and hypophosphatasia. Rising incidence of these disease types are expected to contribute to the segment growth during the forecast period.

Global Skeletal Dysplasia Market By Treatment

Access to a large patient pool in hospitals is propelling the segmental growth
Based on end-users, the market can be divided into hospitals, ambulatory surgical centers, and others. The hospitals segment held a significant market share and is expected to expand at a moderate CAGR during the forecast period. Increase in the number of patients visiting hospitals owing to the advantages such as availability of advanced equipment for diagnosis and access to a large patient pool is driving the growth of the segment.

North America constituted a significant share of the market
In terms of regions, the global skeletal dysplasia market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to expand at a considerable CAGR during the forecast period. The growth is attributed to the factors such as surging research & development initiatives for the treatment of skeletal dysplasia and growing occurrence of the diseases in the region. For instance, as per the recent article published by the American Dental Association, in 2018, X-linked Hypophosphatemia affects around 3,000 children and 12,000 adults in the U.S.

Global Skeletal Dysplasia Market By Region

Segments

Segments Covered in the Report
The global skeletal dysplasia market can be divided based on treatments, end-users, distribution channels, and regions.

By Types
  • X-linked Hypophosphatemia
  • Hypophosphatasia
  • Achondroplasia
  • Fibrodysplasia Ossificans Progressive
  • Multiple Osteochondromas
  • Others
By Treatments
  • Medications
  • Surgery
  • Others
By End-users
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
By Regions
  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa
By Key Players
  • Dr. Reddy’s Laboratories Ltd.
  • Regeneron
  • BioMarin
  • Clementia
  • Ultragenyx Pharmaceutical
  • Novartis AG
  • Eli Lilly and Company
  • Alexion
  • Cipla Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • CELGENE CORPORATION
  • Teva Pharmaceutical Industries Ltd.

Competitive Landscape

Key players in the skeletal dysplasia market include Dr. Reddy’s Laboratories Ltd., Regeneron, BioMarin, Clementia, Ultragenyx Pharmaceutical, Novartis AG, Eli Lilly and Company, Alexion, Cipla Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, CELGENE CORPORATION, and Teva Pharmaceutical Industries Ltd.

Collaborations, mergers, acquisitions, agreements, and partnerships are some growth strategies adopted by these players to strengthen their geographical presence.

Global Skeletal Dysplasia Market By Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Skeletal Dysplasia Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Skeletal Dysplasia Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Skeletal Dysplasia Market - Supply Chain
  4.5. Global Skeletal Dysplasia Market Forecast
     4.5.1. Skeletal Dysplasia Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Skeletal Dysplasia Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Skeletal Dysplasia Market Absolute $ Opportunity
5. Global Skeletal Dysplasia Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Skeletal Dysplasia Market Size and Volume Forecast by Types
     5.3.1. X-linked Hypophosphatemia
     5.3.2. Hypophosphatasia
     5.3.3. Achondroplasia
     5.3.4. Fibrodysplasia Ossificans Progressive
     5.3.5. Multiple Osteochondromas
     5.3.6. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Skeletal Dysplasia Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Skeletal Dysplasia Market Size and Volume Forecast by End Users
     6.3.1. Hospitals
     6.3.2. Ambulatory Surgical Centers
     6.3.3. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Skeletal Dysplasia Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Skeletal Dysplasia Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Skeletal Dysplasia Demand Share Forecast, 2019-2026
8. North America Skeletal Dysplasia Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Skeletal Dysplasia Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Skeletal Dysplasia Market Size and Volume Forecast by Types
     8.4.1. X-linked Hypophosphatemia
     8.4.2. Hypophosphatasia
     8.4.3. Achondroplasia
     8.4.4. Fibrodysplasia Ossificans Progressive
     8.4.5. Multiple Osteochondromas
     8.4.6. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Skeletal Dysplasia Market Size and Volume Forecast by End Users
     8.7.1. Hospitals
     8.7.2. Ambulatory Surgical Centers
     8.7.3. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Skeletal Dysplasia Demand Share Forecast, 2019-2026
9. Latin America Skeletal Dysplasia Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Skeletal Dysplasia Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Skeletal Dysplasia Market Size and Volume Forecast by Types
     9.4.1. X-linked Hypophosphatemia
     9.4.2. Hypophosphatasia
     9.4.3. Achondroplasia
     9.4.4. Fibrodysplasia Ossificans Progressive
     9.4.5. Multiple Osteochondromas
     9.4.6. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Skeletal Dysplasia Market Size and Volume Forecast by End Users
     9.7.1. Hospitals
     9.7.2. Ambulatory Surgical Centers
     9.7.3. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Skeletal Dysplasia Demand Share Forecast, 2019-2026
10. Europe Skeletal Dysplasia Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Skeletal Dysplasia Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Skeletal Dysplasia Market Size and Volume Forecast by Types
     10.4.1. X-linked Hypophosphatemia
     10.4.2. Hypophosphatasia
     10.4.3. Achondroplasia
     10.4.4. Fibrodysplasia Ossificans Progressive
     10.4.5. Multiple Osteochondromas
     10.4.6. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Skeletal Dysplasia Market Size and Volume Forecast by End Users
     10.7.1. Hospitals
     10.7.2. Ambulatory Surgical Centers
     10.7.3. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Skeletal Dysplasia Demand Share Forecast, 2019-2026
11. Asia Pacific Skeletal Dysplasia Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Skeletal Dysplasia Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Skeletal Dysplasia Market Size and Volume Forecast by Types
     11.4.1. X-linked Hypophosphatemia
     11.4.2. Hypophosphatasia
     11.4.3. Achondroplasia
     11.4.4. Fibrodysplasia Ossificans Progressive
     11.4.5. Multiple Osteochondromas
     11.4.6. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Skeletal Dysplasia Market Size and Volume Forecast by End Users
     11.7.1. Hospitals
     11.7.2. Ambulatory Surgical Centers
     11.7.3. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Skeletal Dysplasia Demand Share Forecast, 2019-2026
12. Middle East & Africa Skeletal Dysplasia Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Skeletal Dysplasia Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Skeletal Dysplasia Market Size and Volume Forecast by Types
     12.4.1. X-linked Hypophosphatemia
     12.4.2. Hypophosphatasia
     12.4.3. Achondroplasia
     12.4.4. Fibrodysplasia Ossificans Progressive
     12.4.5. Multiple Osteochondromas
     12.4.6. Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Skeletal Dysplasia Market Size and Volume Forecast by End Users
     12.7.1. Hospitals
     12.7.2. Ambulatory Surgical Centers
     12.7.3. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Skeletal Dysplasia Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Skeletal Dysplasia Market: Market Share Analysis
  13.2. Skeletal Dysplasia Distributors and Customers
  13.3. Skeletal Dysplasia Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Dr. Reddy’s Laboratories Ltd.
     13.4.2. Regeneron
     13.4.3. BioMarin
     13.4.4. Clementia
     13.4.5. Ultragenyx Pharmaceutical
     13.4.6. Novartis AG
     13.4.7. Eli Lilly and Company
     13.4.8. Alexion
     13.4.9.

Methodology

Our Clients

sinopec
Deloitte
General Mills
Dassault Aviation
The John Holland Group
Pfizer
Microsoft
Siemens Healthcare